Loading interactive chart...
1DInterval:
Date Range
1 min
Based on the average brokerage recommendation (ABR), DexCom (DXCM) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
DexCom's (DXCM) first-quarter 2024 results are likely to reflect rising volumes across all channels.
J.P. Morgan analysts expect this week’s results to be “very good” following reports from J&J, Abbott and Intuitive Surgical.